Regulatory and Market Updates
What has changed in compounding rules, enforcement and pricing, and what to verify yourself.
What has changed in compounding rules, enforcement and pricing, and what to verify yourself.
Every page in this section states what we could verify and what we could not. Where a programme publishes nothing, that absence is recorded rather than filled in.
First-year all-in cost
Every page in this section
FDA Warning Letters to Compounded GLP-1 Marketers
What the letters cite, and how to search them yourself.
Semaglutide Shortage Status
The designation that governs lawful compounding.
503A Semaglutide Rules
Patient-specific compounding, and its limits.
503B Semaglutide Rules
Outsourcing facilities and federal oversight.
FDA 503B Bulks List Proposal
A proposal, not a final rule.
Telehealth Marketing Rules
The claims regulators have acted on.
FTC Weight-Loss Advertising Rules
Substantiation and testimonials.
Counterfeit Semaglutide
Falsified product and research-labelled peptide.
Generic Semaglutide Timeline
Launched abroad in 2026; US patents run to the early 2030s.
Provider Price and Availability Changes
What moved since our last capture.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.